Hervé Jacquier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hervé Jacquier has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- Vincent Fihman
Bacteriology Unit - Prevention Diagnosis and Treatment of Infection Department, Henri Mondor Hospital, Créteil, France
9 shared publications - Béatrice Berçot
Université Paris Cité, INSERM, IAME, Paris, France
7 shared publications - Paul-Louis Woerther
Unité de Bactériologie, Département de Prévention, Diagnostic et Traitement des Infections, Hôpitaux Universitaires Henri Mondor, AP-HP , Créteil
7 shared publications - Guilhem Royer
Unité de Bactériologie, Département de Prévention, Diagnostic et Traitement des Infections, Hôpitaux Universitaires Henri Mondor, AP-HP , Créteil
5 shared publications - André Birgy
Université Sorbonne Paris Nord et Université Paris Cité, INSERM, IAME, Paris, France
4 shared publications Anne-Lise Munier
Département de Maladies infectieuses et tropicales, Hôpital Saint-Louis-Lariboisière, Assistance Publique des hôpitaux de Paris , Paris
4 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Shotgun Metagenomics Versus 16S rDNA Sanger Sequencing for the Diagnosis of Blood Culture-Negative Endocarditis: A Draw?
Although valuable for diagnosing blood culture-negative infective endocarditis, 16S rDNA sequencing and metagenomics on valve/vegetation have never been compared using identical DNA extracts. We compared methods on surgical samples from definite, possible, and rejected infective endocarditis involving culture-negative native valves. Positivity rates were similar, with taxonomic resolution being higher for metagenomics.
- 31 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Open AccessShotgun Metagenomics Versus 16S rDNA Sanger Sequencing for the Diagnosis of Blood Culture-Negative Endocarditis: A Draw?
Although valuable for diagnosing blood culture-negative infective endocarditis, 16S rDNA sequencing and metagenomics on valve/vegetation have never been compared using identical DNA extracts. We compared methods on surgical samples from definite, possible, and rejected infective endocarditis involving culture-negative native valves. Positivity rates were similar, with taxonomic resolution being higher for metagenomics.
- Open Access
Chromosomal integration of bla CTX-M redefines the evolutionary trajectory of antibiotic resistance in E. coli through lineage-structured expansion
The global CTX-M pandemic is considered a plasmid-driven phenomenon, yet chromosomal integration of bla CTX-M has been reported in various settings. Screening 451,174 publicly available E. coli genomes and retaining 2,269 CTX-M- E. coli long-read or hybrid assemblies, we found that 33.5% carried at least one chromosomally integrated bla CTX-M . Chromosomal integration was strongly structured by E. coli lineage and CTX-M variant, reaching 68.5% in ST38 and 43.9% in ST131. In the latter, integration rates varied between subclades with modelling, suggesting recent acceleration within the ST131-C2 subclade. Additional resistance genes were frequently co-integrated with bla CTX-M (33%), with architectures largely inherited from plasmid-borne structures. Integrations were mainly IS Ecp1 - or IS 26 -mediated (77.3% and 18.9%, respectively) and occurred across the entire E. coli chromosome without spared zones. bla CTX-M chromosomal integration is a widespread, lineage-structured component of the CTX-M pandemic, providing stable vertical inheritance that complements or may supplant plasmid-mediated dissemination in successful ESBL- E. coli clones.
Open AccessChromosomal integration of bla CTX-M redefines the evolutionary trajectory of antibiotic resistance in E. coli through lineage-structured expansion
The global CTX-M pandemic is considered a plasmid-driven phenomenon, yet chromosomal integration of bla CTX-M has been reported in various settings. Screening 451,174 publicly available E. coli genomes and retaining 2,269 CTX-M- E. coli long-read or hybrid assemblies, we found that 33.5% carried at least one chromosomally integrated bla CTX-M . Chromosomal integration was strongly structured by E. coli lineage and CTX-M variant, reaching 68.5% in ST38 and 43.9% in ST131. In the latter, integration rates varied between subclades with modelling, suggesting recent acceleration within the ST131-C2 subclade. Additional resistance genes were frequently co-integrated with bla CTX-M (33%), with architectures largely inherited from plasmid-borne structures. Integrations were mainly IS Ecp1 - or IS 26 -mediated (77.3% and 18.9%, respectively) and occurred across the entire E. coli chromosome without spared zones. bla CTX-M chromosomal integration is a widespread, lineage-structured component of the CTX-M pandemic, providing stable vertical inheritance that complements or may supplant plasmid-mediated dissemination in successful ESBL- E. coli clones.
- 6 October 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
Beyond the panel: molecular detection is not diagnosis
Over the past decade, molecular diagnostics have become widespread in clinical microbiology, a trend accelerated by the COVID-19 pandemic. Syndromic multiplex PCR panels are increasingly incorporated into routine practice and clinical guidelines, owing to their speed and ease of use. However, their expanding success may overshadow some fundamental principles in bacteriology. In this viewpoint, we argue that the decision to start, continue or stop antibiotics must remain basically clinical; that the detection of nucleic acids is not equivalent to the diagnosis of an infection; and that sample quality, colonization, contamination, off-panel pathogens and prior antibiotic exposure may mitigate the interpretation of molecular results. Available trials show that rapid molecular diagnostics can improve antimicrobial prescribing but their impact on clinical outcomes appears conditional on integration with stewardship programmes. Molecular diagnostics should accelerate and refine clinical reasoning, rather than stand for the key element in the decision to treat bacterial infections.
- 6 October 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
Beyond the panel: molecular detection is not diagnosis
Over the past decade, molecular diagnostics have become widespread in clinical microbiology, a trend accelerated by the COVID-19 pandemic. Syndromic multiplex PCR panels are increasingly incorporated into routine practice and clinical guidelines, owing to their speed and ease of use. However, their expanding success may overshadow some fundamental principles in bacteriology. In this viewpoint, we argue that the decision to start, continue or stop antibiotics must remain basically clinical; that the detection of nucleic acids is not equivalent to the diagnosis of an infection; and that sample quality, colonization, contamination, off-panel pathogens and prior antibiotic exposure may mitigate the interpretation of molecular results. Available trials show that rapid molecular diagnostics can improve antimicrobial prescribing but their impact on clinical outcomes appears conditional on integration with stewardship programmes. Molecular diagnostics should accelerate and refine clinical reasoning, rather than stand for the key element in the decision to treat bacterial infections.
- 27 May 2026
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 39 (3) , e0027425
Dissemination of ESBL-producing Escherichia coli and carriage in the community worldwide: epidemiology, transmission pathways, molecular insights, and practical aspects
SUMMARY: Since the worldwide dissemination of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-Ec) in the early 2000s, ESBL-Ec community carriage has followed divergent epidemiological patterns across regions. Currently, high-income countries (HIC) have a lower prevalence of ESBL-Ec carriage compared to the more concerning prevalence observed in low- and middle-income countries (LMICs). The aim of this review is to summarize the factors that could explain variations in ESBL-Ec prevalence by bridging together information from epidemiological, clinical, and bacterial genetic data. First, geographical differences in ESBL-Ec carriage in the community could be partly related to disparities in socioeconomic levels (e.g., country-level income, Human Development Index) and their associated conditions. Few risk factors associated with ESBL-Ec carriage overlap between LMICs and HICs, except for antibiotic use. Transmission across human, animal, and environmental sectors is much more common in LMICs, whereas inter-human transmission in HICs is more prominent. From the available molecular data, distinct bacterial genetic backgrounds between LMICs (predominantly A and B1 E. coli phylogroups) and HICs (predominantly B2 phylogroup) highlight the clones able to successfully disseminate in these settings. As the dissemination of ESBL-Ec is driven by a complex interplay of socioeconomic, behavioral, and bacterial genetic factors, tailored public health strategies, including antibiotic stewardship and innovative strategies discussed herein, are essential to curb further increases in their prevalence.
- 27 May 2026
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 39 (3) , e0027425
Dissemination of ESBL-producing Escherichia coli and carriage in the community worldwide: epidemiology, transmission pathways, molecular insights, and practical aspects
SUMMARY: Since the worldwide dissemination of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-Ec) in the early 2000s, ESBL-Ec community carriage has followed divergent epidemiological patterns across regions. Currently, high-income countries (HIC) have a lower prevalence of ESBL-Ec carriage compared to the more concerning prevalence observed in low- and middle-income countries (LMICs). The aim of this review is to summarize the factors that could explain variations in ESBL-Ec prevalence by bridging together information from epidemiological, clinical, and bacterial genetic data. First, geographical differences in ESBL-Ec carriage in the community could be partly related to disparities in socioeconomic levels (e.g., country-level income, Human Development Index) and their associated conditions. Few risk factors associated with ESBL-Ec carriage overlap between LMICs and HICs, except for antibiotic use. Transmission across human, animal, and environmental sectors is much more common in LMICs, whereas inter-human transmission in HICs is more prominent. From the available molecular data, distinct bacterial genetic backgrounds between LMICs (predominantly A and B1 E. coli phylogroups) and HICs (predominantly B2 phylogroup) highlight the clones able to successfully disseminate in these settings. As the dissemination of ESBL-Ec is driven by a complex interplay of socioeconomic, behavioral, and bacterial genetic factors, tailored public health strategies, including antibiotic stewardship and innovative strategies discussed herein, are essential to curb further increases in their prevalence.
- Open Access
- 27 May 2026
- Published by Springer Nature in Scientific Reports
Effects of septic shock vasopressors on the fitness of Escherichia coli
Norepinephrine is a catecholamine used as a first-line vasopressor in the management of sepsis. Nevertheless, norepinephrine has been shown to increase fitness and virulence of Escherichia coli, the most predominant facultative anaerobic commensal bacterium in the vertebrate intestinal microbiota and one of the bacteria most frequently implicated in sepsis. Despite high genetic diversity within E. coli species, these effects have been studied on a limited number of archetypal strains. Moreover, the fitness effect of alternative vasopressors, angiotensin II and vasopressin, has never been studied in E. coli. Here, we aimed to explore the effect of norepinephrine, vasopressin and angiotensin II on the fitness of E. coli in stressful media mimicking body compartments (serum-SAPI and urine), using a collection of 21 strains representative of the phylogenetic diversity of the species, and E. coli 536, an urosepsis model strain. We showed that norepinephrine increased the fitness of E. coli, regardless of genetic background, virulence or site of isolation, both in serum-SAPI and urine media. Unlike norepinephrine, angiotensin II and vasopressin display low or no effects on E. coli fitness. Our results bring insights on in vitro effects of norepinephrine, vasopressin and angiotensin II on E. coli, crucial for optimizing sepsis management and guiding future in vivo studies.
- 27 May 2026
- Published by Springer Nature in Scientific Reports
Open AccessEffects of septic shock vasopressors on the fitness of Escherichia coli
Norepinephrine is a catecholamine used as a first-line vasopressor in the management of sepsis. Nevertheless, norepinephrine has been shown to increase fitness and virulence of Escherichia coli, the most predominant facultative anaerobic commensal bacterium in the vertebrate intestinal microbiota and one of the bacteria most frequently implicated in sepsis. Despite high genetic diversity within E. coli species, these effects have been studied on a limited number of archetypal strains. Moreover, the fitness effect of alternative vasopressors, angiotensin II and vasopressin, has never been studied in E. coli. Here, we aimed to explore the effect of norepinephrine, vasopressin and angiotensin II on the fitness of E. coli in stressful media mimicking body compartments (serum-SAPI and urine), using a collection of 21 strains representative of the phylogenetic diversity of the species, and E. coli 536, an urosepsis model strain. We showed that norepinephrine increased the fitness of E. coli, regardless of genetic background, virulence or site of isolation, both in serum-SAPI and urine media. Unlike norepinephrine, angiotensin II and vasopressin display low or no effects on E. coli fitness. Our results bring insights on in vitro effects of norepinephrine, vasopressin and angiotensin II on E. coli, crucial for optimizing sepsis management and guiding future in vivo studies.
- Open Access
- 6 May 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (5) , e0168225
Piperacillin-tazobactam resistance in Klebsiella pneumoniae is often associated with IS 26- mediated bla SHV-1 amplification in a widespread Klebsiella -adapted plasmid
Piperacillin-tazobactam (TZP) resistance in Klebsiella pneumoniae involves diverse mechanisms with unclear prevalence and phenotypic impact. To elucidate these mechanisms, we analyzed K. pneumoniae clinical isolates resistant to TZP but susceptible to cefotaxime and cefepime. Among 53 isolates, 14 were further studied by MIC testing for TZP, amoxicillin-clavulanic acid (AMC), and ceftazidime (CAZ). Short-read sequencing was performed for all 14 isolates and long-read sequencing for two. Core-genome MLST showed that all were unrelated. Two had a bla OXA-1 gene, one also carrying an ompK35 porin gene mutation; two others had the same mutation in the promoter of the chromosomal copy of bla SHV usually associated with overexpression. In the remaining 10, resistance correlated with plasmid-borne bla SHV-1 copies. Nine isolates carried bla SHV-1v1 in the same IS 26 pseudocompound transposon (PTn), corresponding to PTnSHV-L and located on a conserved IncFIB(K)_1_Kpn3 plasmid in eight. The tenth isolate carried PTnSHV-L with a distinct bla SHV-1 variant on both an IncHI1B_1_pNDM-MAR plasmid and a high-copy-number Col-type plasmid. Read depth analysis confirmed that bla SHV copy number correlated with TZP, AMC, and CAZ MICs. Large-scale database screening identified related IncFIB(K)_1_Kpn3 plasmids, strongly associated with K. pneumoniae and frequently carrying a PTnSHV-L marker. Analysis of a K. pneumoniae genome data set confirmed the frequent co-occurrence of this plasmid and the PTnSHV-L marker in strains with multiple bla SHV copies. These findings suggest the emergence of an epidemic plasmid adapted to K. pneumoniae and driving TZP resistance through bla SHV-1 amplification, underscoring the need for genomic surveillance to detect amplification-based resistance overlooked by standard phenotypic or PCR assays.
- 6 May 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (5) , e0168225
Open AccessPiperacillin-tazobactam resistance in Klebsiella pneumoniae is often associated with IS 26- mediated bla SHV-1 amplification in a widespread Klebsiella -adapted plasmid
Piperacillin-tazobactam (TZP) resistance in Klebsiella pneumoniae involves diverse mechanisms with unclear prevalence and phenotypic impact. To elucidate these mechanisms, we analyzed K. pneumoniae clinical isolates resistant to TZP but susceptible to cefotaxime and cefepime. Among 53 isolates, 14 were further studied by MIC testing for TZP, amoxicillin-clavulanic acid (AMC), and ceftazidime (CAZ). Short-read sequencing was performed for all 14 isolates and long-read sequencing for two. Core-genome MLST showed that all were unrelated. Two had a bla OXA-1 gene, one also carrying an ompK35 porin gene mutation; two others had the same mutation in the promoter of the chromosomal copy of bla SHV usually associated with overexpression. In the remaining 10, resistance correlated with plasmid-borne bla SHV-1 copies. Nine isolates carried bla SHV-1v1 in the same IS 26 pseudocompound transposon (PTn), corresponding to PTnSHV-L and located on a conserved IncFIB(K)_1_Kpn3 plasmid in eight. The tenth isolate carried PTnSHV-L with a distinct bla SHV-1 variant on both an IncHI1B_1_pNDM-MAR plasmid and a high-copy-number Col-type plasmid. Read depth analysis confirmed that bla SHV copy number correlated with TZP, AMC, and CAZ MICs. Large-scale database screening identified related IncFIB(K)_1_Kpn3 plasmids, strongly associated with K. pneumoniae and frequently carrying a PTnSHV-L marker. Analysis of a K. pneumoniae genome data set confirmed the frequent co-occurrence of this plasmid and the PTnSHV-L marker in strains with multiple bla SHV copies. These findings suggest the emergence of an epidemic plasmid adapted to K. pneumoniae and driving TZP resistance through bla SHV-1 amplification, underscoring the need for genomic surveillance to detect amplification-based resistance overlooked by standard phenotypic or PCR assays.
- 2 February 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (3)
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
Background and objective: Stenotrophomonas maltophilia is an emerging multidrug-resistant opportunistic pathogen, frequently recovered from deep sites in immunocompromised or critically ill patients. Its clinical relevance is difficult to distinguish from colonization, particularly in polymicrobial infections. To describe the management of patients with deep-site S. maltophilia isolates and to identify factors associated with 28-day mortality. Methods: We conducted a bicentric retrospective study including all patients with at least one deep-site S. maltophilia isolates in two Paris academic hospitals between 2018 and 2020. Demographic, clinical, microbiological and therapeutic data were collected. Appropriate therapy was defined upon in vitro susceptibility. Propensity score weighting was applied to adjust for confounding when assessing the association between appropriate therapy and 28-day mortality. Results: A total of 131 patients were included (67% male; median age 61 years); 63% were immunocompromised and 31% admitted to intensive care. Isolates originated mainly from urine (41%), blood (32%) and respiratory samples (21%); 57% of cultures were polymicrobial. Appropriate therapy was administered to 53% of patients, predominantly trimethoprim/sulfamethoxazole or fluoroquinolones. Overall 28-day mortality was 20%. Mechanical ventilation was independently associated with mortality (HR 4.13, P = 0.001). After propensity score weighting, appropriate therapy was not significantly associated with improved survival. Conclusion: Targeted therapy against S. maltophilia did not reduce 28-day mortality after adjustment, suggesting that patient condition and infection severity may outweigh the effect of targeted treatment. Given the modest sample size, potential confounding, and the secondary nature of this analysis, these findings should be interpreted with caution. Careful clinical evaluation is warranted before initiating specific S. maltophilia therapy.
- 2 February 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (3)
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
Background and objective: Stenotrophomonas maltophilia is an emerging multidrug-resistant opportunistic pathogen, frequently recovered from deep sites in immunocompromised or critically ill patients. Its clinical relevance is difficult to distinguish from colonization, particularly in polymicrobial infections. To describe the management of patients with deep-site S. maltophilia isolates and to identify factors associated with 28-day mortality. Methods: We conducted a bicentric retrospective study including all patients with at least one deep-site S. maltophilia isolates in two Paris academic hospitals between 2018 and 2020. Demographic, clinical, microbiological and therapeutic data were collected. Appropriate therapy was defined upon in vitro susceptibility. Propensity score weighting was applied to adjust for confounding when assessing the association between appropriate therapy and 28-day mortality. Results: A total of 131 patients were included (67% male; median age 61 years); 63% were immunocompromised and 31% admitted to intensive care. Isolates originated mainly from urine (41%), blood (32%) and respiratory samples (21%); 57% of cultures were polymicrobial. Appropriate therapy was administered to 53% of patients, predominantly trimethoprim/sulfamethoxazole or fluoroquinolones. Overall 28-day mortality was 20%. Mechanical ventilation was independently associated with mortality (HR 4.13, P = 0.001). After propensity score weighting, appropriate therapy was not significantly associated with improved survival. Conclusion: Targeted therapy against S. maltophilia did not reduce 28-day mortality after adjustment, suggesting that patient condition and infection severity may outweigh the effect of targeted treatment. Given the modest sample size, potential confounding, and the secondary nature of this analysis, these findings should be interpreted with caution. Careful clinical evaluation is warranted before initiating specific S. maltophilia therapy.
- 17 November 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
Background: Infective endocarditis (IE) is a severe infection requiring efficient, sometimes combined, antibiotic therapy. For β-lactam–susceptible Enteroccus spp., particularly Enterococcus faecalis (EFS), the combination of amoxicillin and ceftriaxone is currently recommended. However, limited data are available for ampicillin-susceptible E. faecium strains (EFM-S). Objectives: To characterize the in vitro synergy of amoxicillin/ceftriaxone combination against clinical isolates of EFM-S and evaluate its clinical relevance. Methods: Twenty-six EFM-S and 10 EFS clinical isolates from the Henri Mondor Hospital (Créteil, France) were tested. EFM-S clades were previously determined by whole-genome sequencing. Checkerboard assays were performed to assess the MICs and synergy across a range of amoxicillin and ceftriaxone concentrations. The fractional inhibitory concentration (FIC) index was computed for each combination, with synergy defined as ΣFIC ≤ 0.5. Results: Amoxicillin and ceftriaxone MIC distributions were comparable between EFM-S (amoxicillin, 0.06–2 mg/L; ceftriaxone, 1 to ≥1024 mg/L) and EFS (amoxicillin, 0.5–2 mg/L; ceftriaxone, 64 to ≥1024 mg/L). Synergy was observed in 21/26 EFM-S and all EFS strains. The five non-synergistic EFM-S strains had low ceftriaxone MICs (1–16 mg/L), probably limiting synergy detection. No difference was observed according to EFM clades. The minimal synergistic concentrations were consistently higher for EFM-S (median amoxicillin, 0.125 mg/L; ceftriaxone, 32 mg/L) compared to EFS (amoxicillin, 0.03 mg/L; ceftriaxone, 2 mg/L). Conclusions: Despite in vitro synergy, the amoxicillin/ceftriaxone combination is clinically irrelevant for EFM-S IE due to unachievable drug concentrations in vivo. These findings support clearer guidelines explicitly excluding this regimen for E. faecium, regardless of β-lactam susceptibility.
- 17 November 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
Background: Infective endocarditis (IE) is a severe infection requiring efficient, sometimes combined, antibiotic therapy. For β-lactam–susceptible Enteroccus spp., particularly Enterococcus faecalis (EFS), the combination of amoxicillin and ceftriaxone is currently recommended. However, limited data are available for ampicillin-susceptible E. faecium strains (EFM-S). Objectives: To characterize the in vitro synergy of amoxicillin/ceftriaxone combination against clinical isolates of EFM-S and evaluate its clinical relevance. Methods: Twenty-six EFM-S and 10 EFS clinical isolates from the Henri Mondor Hospital (Créteil, France) were tested. EFM-S clades were previously determined by whole-genome sequencing. Checkerboard assays were performed to assess the MICs and synergy across a range of amoxicillin and ceftriaxone concentrations. The fractional inhibitory concentration (FIC) index was computed for each combination, with synergy defined as ΣFIC ≤ 0.5. Results: Amoxicillin and ceftriaxone MIC distributions were comparable between EFM-S (amoxicillin, 0.06–2 mg/L; ceftriaxone, 1 to ≥1024 mg/L) and EFS (amoxicillin, 0.5–2 mg/L; ceftriaxone, 64 to ≥1024 mg/L). Synergy was observed in 21/26 EFM-S and all EFS strains. The five non-synergistic EFM-S strains had low ceftriaxone MICs (1–16 mg/L), probably limiting synergy detection. No difference was observed according to EFM clades. The minimal synergistic concentrations were consistently higher for EFM-S (median amoxicillin, 0.125 mg/L; ceftriaxone, 32 mg/L) compared to EFS (amoxicillin, 0.03 mg/L; ceftriaxone, 2 mg/L). Conclusions: Despite in vitro synergy, the amoxicillin/ceftriaxone combination is clinically irrelevant for EFM-S IE due to unachievable drug concentrations in vivo. These findings support clearer guidelines explicitly excluding this regimen for E. faecium, regardless of β-lactam susceptibility.
- 24 April 2025
- Published by American Chemical Society (ACS) in ACS Electrochemistry
- Vol. 1 (6) , 886-896
Microfluidics-Based Electrochemical Detection of Antimicrobial-Resistant DNA Sequence in Lysed Escherichia coli Medium
- 24 April 2025
- Published by American Chemical Society (ACS) in ACS Electrochemistry
- Vol. 1 (6) , 886-896
Microfluidics-Based Electrochemical Detection of Antimicrobial-Resistant DNA Sequence in Lysed Escherichia coli Medium
- 10 April 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (6) , 1647-1655
Clinical features and medical–surgical management overweight the inoculum effect and genotypic characteristics of MSSA in infective endocarditis
Objectives: MSSA remains the leading cause of infective endocarditis (IE) and is responsible for significant mortality. While clinical factors tied to mortality are well documented, possible contributing strain-specific characteristics have not been extensively explored. This study investigates MSSA phenotypic and genotypic characteristics and medical–surgical data related to Day-90 mortality in IE. Methods: We included all patients enrolled in a monocentric prospective cohort (2016–23), with definite or probable MSSA IE. Cefazolin and oxacillin MICs and inoculum effects were determined by broth microdilution. Genotyping analysis and BlaZ typing were obtained from WGS. Phenotypic and genotypic characteristics of strains and clinical risk factors were confronted with Day-90 mortality. Results: Eighty-eight patients with MSSA IE were included. The most frequent clinical presentations were left-sided native valve IE (25/88), left-sided prosthetic valve IE (12/88) and right-sided IE (19/88). Day-90 mortality rate was 39% (34/88). Most patients were treated with antistaphylococcal penicillin as a primary antibiotic (60/88). The main MSSA clonal complexes identified were CC398 (17/88), CC30 (13/88) and CC5 (13/88). Cefazolin inoculum effect was observed in 18/88 strains, and oxacillin inoculum effect in 13/88. Overall, 15/88 isolates exhibited an inoculum effect on primary antibiotic therapy. Factors independently associated with improved outcomes included cardiac surgery [hazard ratio (HR) 0.34, 95% CI (0.13–0.89)] and source control [HR 0.21, 95% CI (0.03–0.53)]. Neither genetic background, blaZ carriage, nor in vitro inoculum effect to the primary antibiotherapy was associated with Day-90 mortality. Conclusions: This cohort of MSSA IE did not find any microbiological factors correlated with Day-90 mortality. Clinical features and infection management appear to be the main factors in the prognosis of MSSA IE.
- 10 April 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (6) , 1647-1655
Clinical features and medical–surgical management overweight the inoculum effect and genotypic characteristics of MSSA in infective endocarditis
Objectives: MSSA remains the leading cause of infective endocarditis (IE) and is responsible for significant mortality. While clinical factors tied to mortality are well documented, possible contributing strain-specific characteristics have not been extensively explored. This study investigates MSSA phenotypic and genotypic characteristics and medical–surgical data related to Day-90 mortality in IE. Methods: We included all patients enrolled in a monocentric prospective cohort (2016–23), with definite or probable MSSA IE. Cefazolin and oxacillin MICs and inoculum effects were determined by broth microdilution. Genotyping analysis and BlaZ typing were obtained from WGS. Phenotypic and genotypic characteristics of strains and clinical risk factors were confronted with Day-90 mortality. Results: Eighty-eight patients with MSSA IE were included. The most frequent clinical presentations were left-sided native valve IE (25/88), left-sided prosthetic valve IE (12/88) and right-sided IE (19/88). Day-90 mortality rate was 39% (34/88). Most patients were treated with antistaphylococcal penicillin as a primary antibiotic (60/88). The main MSSA clonal complexes identified were CC398 (17/88), CC30 (13/88) and CC5 (13/88). Cefazolin inoculum effect was observed in 18/88 strains, and oxacillin inoculum effect in 13/88. Overall, 15/88 isolates exhibited an inoculum effect on primary antibiotic therapy. Factors independently associated with improved outcomes included cardiac surgery [hazard ratio (HR) 0.34, 95% CI (0.13–0.89)] and source control [HR 0.21, 95% CI (0.03–0.53)]. Neither genetic background, blaZ carriage, nor in vitro inoculum effect to the primary antibiotherapy was associated with Day-90 mortality. Conclusions: This cohort of MSSA IE did not find any microbiological factors correlated with Day-90 mortality. Clinical features and infection management appear to be the main factors in the prognosis of MSSA IE.